Looking for volunteers
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
NCT05753306 · Mayo Clinic · Updated 8 April 2026
- What is being tested
- Cisplatin; Computed Tomography; Gastrectomy; Magnetic Resonance Imaging; Positron Emission Tomography; Questionnaire Administration; Paclitaxel; Hyperthermic Intraperitoneal Chemotherapy
- For
- Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 18 years to 80 years. About 40 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 20 April 2023, ends 25 March 2030. Registered 3 March 2023.
- Results
- None posted yet.
In the researchers' words
This phase II clinical trial tests how well robotic cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with gastric cancer that has spread to the tissue that lines the wall of the abdominal cavity (peritoneum). Gastric cancer is the third leading cause of cancer related deaths worldwide and peritoneal metastasis are found in 30% of patients at time of diagnosis. Patients with peritoneal metastasis have poor survival rates. Traditional surgery is done with a large incision and has a high complication rate and longer hospital stays. Robot assisted (robotic) cytoreduction is a surgical option that uses small incisions and there is less risk of complications. HIPEC involves infusing heated chemotherapy into the abdominal cavity during surgery. Robotic cytoreduction together with HIPEC may improve recovery and decrease complications after surgery.
Sites
- Mayo Clinic in RochesterRochester, Minnesota, United States